These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24926422)

  • 1. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.
    Hansen RN; Ramsey SD; Lalla D; Masaquel A; Kamath T; Brammer M; Hurvitz SA; Sullivan SD
    Springerplus; 2014; 3():259. PubMed ID: 24926422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
    Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
    Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
    Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
    J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost comparison of capecitabine in patients with breast cancer.
    Rugo HS; Kohles J; Schulman KL
    Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
    Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
    Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
    Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
    Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V
    J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
    Schwartzberg LS; Cobb P; Walker MS; Stepanski EJ; Houts AC
    Support Care Cancer; 2009 Aug; 17(8):1081-8. PubMed ID: 19148686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.
    Force RW; Pugmire BA; Culbertson VL
    Am Health Drug Benefits; 2010 Jul; 3(4):276-84. PubMed ID: 25126321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
    Piwko C; Prady C; Yunger S; Pollex E; Moser A
    Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.
    Rak Tkaczuk KH
    Breast Cancer (Auckl); 2011 Jan; 5():1-14. PubMed ID: 21494397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
    Ghate SR; Li Z; Tang J; Nakasato AR
    Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.